Call us : USA : 1-631-466-5530; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News
Therapeutic Antibodies

Therapeutic Antibodies

Creative Biolabs offers a full range of therapeutic antibodies currently available for research of a wide variety of diseases.

Learn More
Hi-affi™ Recombinant Antibodies

Hi-affi™ Recombinant Antibodies

With optimized library construction and screening processes using hybridoma or phage display technology, We have developed proprietary procedures for Hi-Affi™ recombinant antibody production.

Learn More
Single-domain Antibodies

Single-domain Antibodies

SdAbs are single-domain antibodies (SdAbs) derived from the variable regions of heavy chain of Camelidae immunoglobulins, also called VHHs. Creative Biolabs provides the most complete collection of SdAb products the world has ever had.

Learn More
Antibody Engineering Service

Antibody Engineering Service

With our unique platform, Creative Biolabs provide antibody engineering service, especially glycoengineering for our clients all over the world.

Learn More

Alternatives to Cope with Lengthy Clinical Development Process for COVID-19

April 5, 2020News, Recombinant Antibody R&DClinical Development, SARS-CoV-2, therapeutic antibodybiorab

The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…

A Brief Introduction of MERS-CoV

February 21, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

In 2012, MERS-CoV (Middle East Respiratory Syndrome Coronavirus) was found in Saudi Arabia. The early labor symptoms caused by the viruse are similar to SARS (Severe Acute Respiratory Syndrome). Therefore, MERS-CoV isRead More…

Focus on SARS-CoV-2

February 19, 2020Recombinant Antibody R&DCoronavirus, COVID-19, SARS-CoV-2biorab

As we all know, a new crown pneumonia epidemic suddenly swept China at the end of 2019 and even affected the whole world. On January 30, 2020, WHO announced that the epidemicRead More…

Do You Know SARS-CoV ?

February 18, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

In 2002, severe acute respiratory syndrome occurred in Guangdong, China, and spread throughout the world, causing a global epidemic of infectious diseases. The culprit of this incident was SARS-CoV (Severe Acute RespiratoryRead More…

What is Coronavirus ?

February 17, 2020Recombinant Antibody R&DCoronavirus, MERS-CoV, SARS-CoVbiorab

Recently, a virus called SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) caused an epidemic with pneumonia as the main symptom. This SARS-CoV-2 is a coronavirus, so what exactly is a coronavirus? OverviewRead More…

Cancer Res: The Causes of Chemotherapy Resistance in Breast Cancer

June 26, 2019NewsBreast Cancer, Chemotherapy Resistancebiorab

According to a study recently published in Cancer Research by researchers and colleagues at the Belvich Institute of Biomedicine at the University of Barcelona, a large number of replicated chromosome regions areRead More…

Scientists Found that Potassium Ions are the Key to Controlling the Anticancer Ability of T cells

April 17, 2019NewsCancer, Potassium Ion, T cellbiorab

A study led by scientists at the Center for Cancer Research (CCR) at the American National Cancer Institute (NCI) has revealed a way to promote the continued growth of tumors in theRead More…

3D Bio-printing Model Changes Anti-cancer Drug Development and Anti-tumor Therapy

February 19, 2019News3D Model, Bio-printing, Cancerbiorab

Researchers at the University of Minnesota have developed a way to study cancer cells, which could lead to new and more effective treatments. They have developed a new method to study theseRead More…

Nine characteristics shared by the most successful mAb

February 1, 2019News, Therapeutic Antibody R&Dantibody discovery, monoclonal antibody drug, therapeutic antibodybiorab

The path to finding a therapeutic antibody that leads to significant medical improvements is often complicated, long, and costly. Many criteria have to be taken into account in order to begin theRead More…

Sixteen New Tumor Drugs First Approved in 2018

December 28, 2018News, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

In 2018, from the approval of JNJ’s apalutamide in the United States on February 14 to that of larotrectinib on November 26, a total of 16 new tumor drugs were approved forRead More…

Posts navigation

  • 1
  • 2
  • 3
  • Next »

Categories

  • Antibody Engineering R&D
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • Alternatives to Cope with Lengthy Clinical Development Process for COVID-19
  • A Brief Introduction of MERS-CoV
  • Focus on SARS-CoV-2
  • Do You Know SARS-CoV ?
  • What is Coronavirus ?

Archives

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Designed and Developed by templatesnext